Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Bookworm28on Nov 18, 2021 6:51pm
197 Views
Post# 34143288

RE:Nasal Spray to cure AD! Human Trials

RE:Nasal Spray to cure AD! Human Trials
JackRedwood wrote:

It seems like they are already testing on Humans with a new AD drug that is used as a Nasal Spray! Clinical Trials are being done as we speak. 

PMN like their so called Covid Test is wasting time or diluting the Company into oblivion. 

Not fair to long term Shareholders! 

article;
https://www.cbsnews.com/news/alzheimers-disease-nasal-vaccine-human-trial-to-begin-at-boston-hospital/



I feel your frustration. I'm trying to figure out if these guys are for real or not. I look over the year's NRs, and they apparently have this fantastic PM310 antibody, but not much is happening. I know this type of tech progresses slowly, but they need to give us something tangible. Something other than their cell-line NR from May. What do they do day to day? Do they have specific people working on specific aspects of PM310? Dunno. I haven't seen a single job on their website over the last year. One thing that does impress me, is their ability to raise money. Their 'distringuished' group of investors from Boston must see something.

Can't wait for them to get this consolidation over with and some NRs about PM310, a less NRs about biogen and aducanumab, COVID, etc.. I'd really like to see our distinguished investors from Boston prompt a change at the top. It would, in my opinion, go a long way in attracting some serious attention from new investors. Too little has been happening for too long. GLTA.


<< Previous
Bullboard Posts
Next >>